Use of atropine 0.01% eye drops for controlling myopia progression in children
Keywords:
Myopia, atropine, ophthalmic solutions, adverse effects, children.Abstract
Introduction: Globally, an increase in the prevalence of myopia along with its association with other illnesses have been evidenced. A great number of investigations certify the effectiveness of using atropine 0.01% eye drops and indicate that it is the most effective method to control myopia progression.
Objective: To show the effectiveness of atropine 0.01% eye drops for the control of myopia progression as well as its adverse effects in the pediatric population.
Material and Methods: A bibliographic review was performed in different databases and the Virtual Health Library from January 2003 to December 2022. Keywords such as myopia, atropine, ophthalmic solutions, adverse effects, and children were used; they were also combined with OR, AND, NOT boolean operators. A total of 178 references were obtained; of them, 47 ones were selected because they were considered of higher relevance and novelty.
Development: Myopia shows itself a wide geographic distribution as well as a variable prevalence due to genetic, environmental, socioeconomic, and cultural factors. Several research studies indicate that the use of atropine 0.01% eye drops is the most effective method to control myopia progression, reporting few adverse reactions of low intensity. There are still many unanswered questions about its preparation, long-term results, and the rebound effect once the treatment is concluded.
Conclusions: Atropine 0.01% eye drops have demonstrated to be effective in the treatment of myopia progression in pediatric patients, with no significant adverse effects. Analytical studies must be carried out to evaluate its effectiveness and adverse effects in the Cuban pediatric population.
Downloads
References
1. Pérez I. Tratamiento médico de la miopía. Acta Estrabológica [Internet]. 2018 [Citado 02/01/2023];2:79-94. Disponible en: https://www.estrabologia.org/actas/Acta_2_2018/02-REVISION%20Dra.%20Ines%20Perez.pdf
2. Alberto Y, Paneca R, Garrido L. Refracción. En: Santiesteban Freixas R. Oftalmología Pediátrica [Internet]. La Habana: Editorial Ciencias Médicas; 2018.pp.114-25 [Citado 02/01/2023]. Disponible en: http://www.bvscuba.sld.cu/libro/oftalmologia-pediatica-2da-ed/
3. Chierigo A, Ferro Desideri L, Traverso CE, Vagge A. The Role of Atropine in Preventing Myopia Progression: An Update. Pharmaceutics [Internet]. 2022 [Citado 02/01/2023];14(5):900. Disponible en: https://www.mdpi.com/1999-4923/14/5/900
4. Macedo IB. O uso do colirio de atropina como estratégia terapêutica para retardar o desenvolvimento de miopía em crianças. Rev Med Minas Gerais [Internet]. 2020 [Citado 02/01/2023];30(6):S33-S36. Disponible en: https://rmmg.org/content/imagebank/pdf/v30s6.pdf#page=36
5. Chia A. Atropine for the treatment of chilhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology [Internet]. 2012 [Citado 02/01/2023];119:347-54. Disponible en: https://www.snec.com.sg/patient-care/specialties-and-services/clinics-centres/myopia-centre/Documents/Atropine-Treatment-of-Myopia-2.pdf
6. Díaz M, Pinazo MD. La atropina superdiluida a 0,01 % frena el aumento de miopía en niños-adolescentes. Un estudio a largo plazo 5 años de evolución: seguridad y eficacia. Arch Soc Esp Oftalmol [Internet]. 2019 [Citado 02/01/2023];94. Disponible en: https://medes.com/publication/134145
7. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmol [Internet]. 2016 [Citado 02/01/2023];123(5):1036-42. Disponible en: http://starvision.vn/wp-content/uploads/tailieu/Myopia%202000-2050.pdf
8. Molina-Curbelo D, Ruiz-Aday A, Valdés-Vales V, Rodríguez-Molina F, Cabrera-Rodríguez H. Comportamiento de los defectos refractivos en estudiantes de la escuela primaria Ignacio Agramonte y Loynaz. Cienfuegos 2015. Medisur [Internet]. 2017 [Citado 02/01/2023];15(2):202-209. Disponible en: https://medisur.sld.cu/index.php/medisur/article/view/3546
9. León Vázquez T, De la Torre Lara N, Cordero Caboverde D, Reyes Peña I, La O Lozano Y, Monteagudo García M. Defectos refractivos en estudiantes de la escuela “Salvador Allende”. Rev Cubana Tec Salud [Internet]. 2021 [Citado 02/01/2023];12(4):37-45. Disponible en: https://revtecnologia.sld.cu/index.php/tec/article/view/2313
10. Sibello-Deustua S, Nambótya-Caluyua A, Méndez-Sánchez T, Pons-Castro L, Hernández-Perugorría A. Impacto de la COVID-19 en la progresión de la miopía en niños. Revista Cubana de Oftalmología [Internet]. 2023 [Citado 02/01/2023]; 36(1):e1606. Disponible en: https://revoftalmologia.sld.cu/index.php/oftalmologia/article/view/1606
11. Sankaridurg P, Conrad F, Tran H, Zhu J. Controlling progression of myopia: optical and pharmaceutical strategies. Asia-Pac J Ophthalmol [Internet]. 2018 [Citado 25/10/2023];7(6):405-14. Disponible en: https://journals.lww.com/apjoo/FullText/2018/11000/Controlling_Progression_of_Myopia_Optical_and.6.aspx
12. Gong Q. Efficacy and adverse effects of atropine in chilhood myopia. JAM Ophthalmol [Internet]. 2017 [Citado 25/10/2023];135(6):624-30. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710262/
13. Zloto O. Current trends among pediatric ophthalmologists to decrease myopia progression-an international prespective. Graefe´s Archive for Clinical and Experimental Ophthalmology [Internet]. 2018 [Citado 25/10/2023];256(10):2015-7. Disponible en: https://core.ac.uk/download/pdf/187423816.pdf
14. Sánchez-González JM, De-Hita-Cantalejo C, Baustita-Llamas MJ, Sánchez-González MC, Capote-Puente R. The Combined Effect of Low-dose Atropine with Orthokeratology in Pediatric Myopia Control: Review of the Current Treatment Status for Myopia. J Clin Med [Internet]. 2020 [Citado 25/10/2023];9(8):2371. Disponible en: https://pdfs.semanticscholar.org/dd25/2e17c58bfa2f9a4c96305d1b660a7c8d69e0.pdf
15. Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol [Internet]. 2020 [Citado 25/10/2023];104:1535-41. Disponible en: https://bjo.bmj.com/content/bjophthalmol/104/11/1535.full.pdf
16. Upadhyay A, Beuerman R. Biological mechanisms of atropine control of myopia. Eye Contact Lens [Internet]. 2020 [Citado 25/10/2023];46(3):129-35. Disponible en: https://journals.lww.com/claojournal/Fulltext/2020/05000/Biological_Mechanisms_of_Atropine_Control_of.2.aspx
17. Sacchi M, Serafino M, Villani E, Tagliabue E, Luccarelli S, Bonsignore F, et al. Eficacy of atropine 0.01 % for the treatment of childhood myopia in European patients. Acta Ophthalmol [Internet]. 2019 [Citado 25/10/2023];97(8):1136-40. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/aos.14166
18. Austermann H, Schaeffel F, Mathis U, Hund V, Mußhoff F, Ziemssen F, et al. Corneal penetration of low-dose atropine eye drops. J Clin Med [Internet]. 2021 [Citado 25/10/2023];10(588):[Aprox. 12 p.]. Disponible en: https://www.mdpi.com/2077-0383/10/4/588/htm
19. Larkin GL, Tahir A, Epley KD, Beauchamp CL, Tong JT, Clark RA. Atropine 0.01 % eye drops for myopia control in american children: a multiethnic sample across three US sites. Ophthalmol Ther [Internet]. 2019 [Citado 25/10/2023];8:589-98. Disponible en: https://link.springer.com/content/pdf/10.1007/s40123-019-00217-w.pdf
20. González del Valle F, Martín de Rosales Cabrera AM. Tratamiento farmacológico de la miopía pediátrica. En su: 10 temas candentes en oftalmología y farmacia hospitalaria [Internet]. Madrid: Sociedad Española de Farmacia Hospitalaria; 2021.pp.52-8 [Citado 25/10/2023]. Disponible en: https://www.researchgate.net/profile/Jose-Maria-Herreros-2/publication/357367889_Coordinadores_10_TEMAS_CANDENTES_EN_OFTALMOLOGIA_Y_FARMACIA_HOSPITALARIA/links/61cad885da5d105e5500f320/Coordinadores-10-TEMAS-CANDENTES-EN-OFTALMOLOGIA-Y-FARMACIA-HOSPITALARIA.pdf
21. Berton B, Chennell P, Yessaad M, Bouattour Y, Jouannet M, Wasiak M, et al. Stability of ophthalmic atropine solutions for child myopia control. Pharmaceutics [Internet]. 2020 [Citado 25/10/2023];12(781):[Aprox. 17 p.]. Disponible en: https://www.researchgate.net/publication/343716631_Stability_of_Ophthalmic_Atropine_Solutions_for_Child_Myopia_Control/link/5f3bcd6b299bf13404cd7136/download
22. Sri-in J, Sisan W, Kingkhangphloo P, Jutasompakorn P, Chandranipapongse W, Chatsiricharoenkul S, et al. Stability and sterility of extemporaneously prepared 0.01% atropine ophthalmic solution in artificial tears and balanced salt solution. Siriraj Med J [Internet]. 2022 [Citado 25/10/2023];74(2):91-99. Disponible en: https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/255967/174215
23. Saito J, Imaizumi H, Yamatani A. Physical, chemical, and microbiological stability study of diluted atropine eye drops. J Pharm Health Care Sci [Internet]. 2019 [Citado 25/10/2023];5:25. Disponible en: https://jphcs.biomedcentral.com/articles/10.1186/s40780-019-0154-2
24. Wongwirawat N, Kuchonthara N, Boontanomwong S, Pongpirul K. Hospital-prepared low-dose atropine eye drops for myopia progression control using atropine sulfate injection diluted in normal saline and lubricants. BMC Res Notes [Internet]. 2022 [Citado 25/10/2023];15(1):342. Disponible en: https://assets.researchsquare.com/files/rs-650760/v3/8311fe8e-d1d9-4f62-a85e-61058fcdc3a4.pdf?c=1635148762
25. Chia A. Atropine for the treatment of chilhood myopia: Changes after stopping atropine 0.01 %, 0.1 % and 0.5 %. Am J Ophthalmol [Internet]. 2014 [Citado 25/10/2023];157(2):451-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24315293/
26. Chia A. Five-year clinical trial on atropine for the treatment of myopia 2. Ophthalmology [Internet]. 2016 [Citado 25/10/2023];123(2):391-9. Disponible en: https://www.aaojournal.org/article/S0161-6420(15)00675-2/fulltext
27. Yam JC, Jiang Y, Tang SM, Law A, Chan JJ, Wong E, et al. Low-concentration atropine for myopia progression (LAMP) study a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology [Internet]. 2019 [Citado 25/10/2023];126(1):113-24. Disponible en: https://static1.squarespace.com/static/5d9741a56b45d153f8f5f753/t/5da35a00ae38d1604198d75d/1570986498529/PIIS0161642018302859.pdf
28. Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology [Internet]. 2020 [Citado 25/10/2023];127:910-9. Disponible en: https://www.researchgate.net/profile/Fen-Fen-Li/publication/339077501_Two-Year_Clinical_Trial_of_the_Low-Concentration_Atropine_for_Myopia_Progression_LAMP_Study_Phase_2_Report/links/5e85b8ed4585150839b61b75/Two-Year-Clinical-Trial-of-the-Low-Concentration-Atropine-for-Myopia-Progression-LAMP-Study-Phase-2-Report.pdf
29. Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-year clinical trial of low-concentration atropine for myopia progression study: continued versus washout: phase 3 report. Ophthalmology [Internet]. 2022 [Citado 25/10/2023];129(3):308-321. Disponible en: https://visionsource-br.com/wp-content/uploads/sites/1646/2022/03/Yam-LAMP-Washout-2021.pdf
30. Clark TY, Clark RA. Atropine 0.01 % eyedrops significantly reduce the progression of childhood myopia. J Ocul Pharmacol Ther [Internet]. 2015 [Citado 25/10/2023];31(9):541-5. Disponible en: https://journals.lww.com/claojournal/Fulltext/2020/05000/Biological_Mechanisms_of_Atropine_Control_of.2.aspx
31. Zhang X, Wang Y, Zhou X, Qu X. Analysis of Factors That May Affect the Effect of Atropine 0.01% on Myopia Control. Front Pharmacol [Internet]. 2020 [Citado 25/10/2023];11:01081. Disponible en: https://www.frontiersin.org/articles/10.3389/fphar.2020.01081/full
32. Myles W, Dunlop, McFadden SA. The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children. J Clin Med [Internet]. 2021 [Citado 25/10/2023];10(7):1444. Disponible en: https://www.mdpi.com/2077-0383/10/7/1444
33. Azuara A, Logan N, Strang N, Saunders K, Allen PM, Weir R, et al. Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)—study protocol. Br J Ophthalmol [Internet]. 2020 [Citado 25/10/2023];104(7):[Aprox. 6 p.]. Disponible en: https://bjo.bmj.com/content/bjophthalmol/104/7/950.full.pdf
34. Wang Y, Yao J, Qu X. Atropine 0.01 % for the control of myopia in chinese children: effect on accommodation functions and pupil size. Journal of Ophthalmology [Internet]. 2020 [Citado 25/10/2023];8(3):427-33. Disponible en: https://downloads.hindawi.com/journals/joph/2020/7525180.pdf
35. Ali H, Rehman M, Ali Q, Shahzad MA, Ali A, Humayun B. Safety and efficacy of different concentrations of atropine in retarding the myopia progression. Ophthalmology Update [Internet]. 2020 [Citado 25/10/2023];18(4):16-22. Disponible en: https://www.researchgate.net/publication/344676032_Safety_and_Efficacy_of_Different_Concentrations_of_Atropine_in_Retarding_the_Myopia_Progression/link/5f88bfd9458515b7cf84e23b/download
36. Sanwaliya B, Nainiwal SK, Porwal R, Sarraf A, Sharma V. Placebo-controlled, safety and efficacy study of topical atropine (0.01%) in myopic children. Indian J Clin Exp Ophthalmol [Internet]. 2020 [Citado 25/10/2023];6(4):610-5. Disponible en: https://pdfs.semanticscholar.org/49a1/a8a77300fc8559303f528e9f0a1054d7f13d.pdf
37. Moriche-Carretero M, Revilla-Amores R, Díaz-Valle D, Morales-Fernández L, Gómez-de-Liaño R. Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01 % eye-drops. J Fr Ophtalmol [Internet]. 2021 [Citado 25/10/2023];44(10):1499-1504.Disponible en: https://pubmed.ncbi.nlm.nih.gov/34774348/
38. Jong M, Wolffsohn JS. Reporte del Control Clínico de ensayos e instrumentación en Miopía IMI. [Internet]. Australia: International Myopia Institute; 2019 [Citado 25/10/2023]. Disponible en: https://myopiainstitute.org/wp-content/uploads/2020/09/IMI-Clinical-Myopia-Control-Trials-and-Instrumentation-Report_SPANISHFINALv2.pdf
39. Pei-Chang W, Meng-Ni Ch, Choi J, Chen H, Wu G, Ohno-Matsui K, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye [Internet]. 2019 [Citado 25/10/2023];33:3-13. Disponible en: https://www.nature.com/articles/s41433-018-0139-7
40. Li FF, Yam JC. Low-concentration atropine eye drops for myopia progression. Asia-Pac J Ophthalmol [Internet]. 2019 [Citado 25/10/2023];8(5):360-5. Disponible en: https://journals.lww.com/apjoo/Fulltext/2019/10000/Low_Concentration_Atropine_Eye_Drops_for_Myopia.3.aspx
41. Zhao Y, Feng K, Liu RB, Pan JH, Zhang LL, Xu ZP, et al. Atropine 0.01 % eye drops slow myopia progression: a systematic review and Meta-analysis. Int J Ophthalmol [Internet]. 2019 [Citado 25/10/2023];12(8):1337-43. Disponible en: http://www.ijo.cn/en_publish/2019/8/20190816.pdf
42. CECMED. Resumen de las características del producto Atropina 1 % colirio. [Internet]. La Habana: CECMED; 2016 [Citado 25/10/2023]. Disponible en: https://www.cecmed.cu/registro/rcp/medicamentos/atropina-1
43. Joachimsen L, Farassat N, Bleul T, Böhringer D, Lagrèze WA, Reich M. Side effects of topical atropine 0.05 % compared to 0.01 % for myopia control in German school children: a pilot study. Int Ophthalmol [Internet]. 2021 [Citado 25/10/2023];41(6):2001-8. Disponible en: https://link.springer.com/article/10.1007%2Fs10792-021-01755-8
44. Cheng J, Yang Y, Kong X, Zeng L, Chen Z, Xu J, et al. The effect of 0.01% atropine eye drops on the ocular surface in children for the control of myopia—the primary results from a six-month prospective study. Ther Clin Risk Manag [Internet]. 2020 [Citado 25/10/2023];16:735-40 Disponible en: https://www.scienceopen.com/document_file/b9ab114f-7f72-4cab-8756-80a2020fbf4e/PubMedCentral/b9ab114f-7f72-4cab-8756-80a2020fbf4e.pdf
45. Tzu W, Hsin Ch, Mao J, Yen Ch, Ting Ch, Chi L. Evaluating the effect of topical atropine use for myopia control on intraocular pressure by using Machine Learning. J Clin Med [Internet]. 2021 [Citado 25/10/2023];10(111):[Aprox.8 p.]. Disponible en: https://www.mdpi.com/2077-0383/10/1/111
46. Teng Y, Tzu W, Yuan W, Shen Ch, Shiow L. STROBE-compliant case–control study. Effects of cumulative doses of topical atropine on intraocular pressure and myopia progression. Medicine [Internet]. 2020 [Citado 25/10/2023];99(48):[Aprox. 7 p.]. Disponible en: https://journals.lww.com/md-journal/Fulltext/2020/11250/A_STROBE_compliant_case_control_study__Effects_of.11.aspx
47. Galán MM, Szeps A, Irigaray LF, Kotlik C, Rodríguez G, Aguirre R, et al. Consenso sobre el manejo de la miopía en la edad de progresión. Oftalmol Clin Exp [Internet]. 2022 [Citado 25/10/2023];15(2):e115-e136. Disponible en: https://revistaoce.com/index.php/revista/article/view/142/214
48. Khanal S, Phillips JR. Which low‐dose atropine for myopia control?. Clin Exp Optom [Internet]. 2020 [Citado 25/10/2023];103(2):230-2. Disponible en: https://www.tandfonline.com/doi/epdf/10.1111/cxo.12967?needAccess=true&role=button
49. Zhang J, Jiao J, Niu M, Gao X, Zhang G, Yu H, et al. Ten years of knowledge of nano-carrier based drug delivery systems in ophthalmology: current evidence, challenges, and future prospective. Intern J Nanomed [Internet]. 2021 [Citado 25/10/2023];16:6497-6530. Disponible en: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8473849&blobtype=pdf
Download PDF
